Chiusura precedente | 1,8620 |
Aperto | 1,6980 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 1,6980 - 1,6980 |
Intervallo di 52 settimane | 1,6980 - 1,6980 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 106,474M |
Beta (5 anni mensile) | 1,92 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,9260 |
Prossima data utili | 27 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
RICHMOND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022. Recent Highlights and Accomplishments Reported revenue of $2.6 million in the first quarter of 2022Strong cash position of $36.2 million at March 31, 2022Booked a total of 23 EksoNR units in the first quarter of 2022Secured three mult
RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webca
RICHMOND, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments Reported record revenue of $4.1 million in the fourth quarter of 2021Achieved gross margin of approximately 59% in the fourth quarter of 2021Booked a total of 30 EksoNR units in the f